**Review article:** Understanding the burden of refractory myasthenia gravis

**Supplementary file**

**Supplementary Table 1.** Definitions of refractory MG reported in publications cited in the review article.

| Reference                  | Definition of refractory MG                                                                                                                                                                                                 | Classification of definition\(^a\) | Comment                                           |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------|
| Afanasiev et al. 2017\(^1\) | Severe MG symptoms (MGFA class IV or V) despite optimal use of prednisone and ≥1 immunosuppressant for ≥6 months; or past history of severe MG symptoms and now stabilized (MGFA class I–III) at the price of chronic treatment with IVIg and/or PE with regular programmed hospitalizations or with prednisone and immunosuppressants but with side effects necessitating their withdrawal | 1,2,3                             | Monocentric retrospective study (n = 28)           |
| Ando et al. 2015\(^2\)     | Unstable MG defined as fluctuating MG that limits activities of daily life occasionally due to muscle weakness or fatigue, or deteriorated MG symptoms after medical treatment when compared with pretreatment symptoms (in comparison with stable MG: controlled or ameliorated preoperative symptoms when compared with pretreatment symptoms) | 1                                 | Unstable n = 8; stable n = 47                     |
| Baek et al. 2007\(^3\)     | MuSK-positive generalized MG, refractory to steroids, IVIg, immunosuppressants, thymectomy, and less responsive to plasmapheresis                                                                                           | 1                                 | Case study                                        |
| Barnett et al. 2013\(^4\)  | Patients with moderate to severe MG and worsening symptoms who require IVIg or PE                                                                                                                                            | 2                                 | Small study (n = 62)                              |
| Beecher et al. 2018\(^5\)  | Suboptimal response (unchanged or worsening clinical status) to ≥2 immunosuppressive therapies; inability to tolerate side effects related to multiple immunosuppressive therapies; inability to reduce steroid dose without relapse; or requirement for maintenance IVIg infusions or PE | 1,2,3                             | Small prospective open-label study (n = 22)       |
| Reference            | Definition of refractory MG                                                                 | Classification of definition | Comment                                      |
|----------------------|---------------------------------------------------------------------------------------------|------------------------------|----------------------------------------------|
| Blaha et al. 2010⁶    | Severe condition despite thymectomy and drug therapy (including corticosteroids, immunosuppressive drugs, and repeated doses of immunoglobulins) | 1                            | Small study (n = 6)                          |
| Bourque et al. 2016⁷ | Patients with no prior use of IVIg but refractory to conventional oral therapies             | 1                            | Case series (n = 3)                          |
| Buzzard et al. 2015⁸ | Resistance, toxicities, or contraindications to conventional immunosuppressive treatments, and/or dependence on PE or IVIg | 1,2,3,4                      | Case series (n = 6)                          |
| Cereda et al. 2009⁹  | Refractory course with increasingly frequent exacerbations that progressively require increasing doses of immunosuppressant (corticosteroids followed by azathioprine), frequent visits for plasmapheresis (in the case of a myasthenic crisis, approximately every 3 months), and regular use of IVIg (once per month) | 5                            | Case history                                 |
| Collongues et al. 2012¹⁰ | Failure to respond to thymectomy and ≥2 immunosuppressive drugs, including steroids          | 1                            | Retrospective multicenter study (refractory MG, n = 13; nonrefractory MG, n = 7) |
| Engel-Nitz et al. 2018¹¹ | Patients with past or current use of ≥3 immunosuppressive therapies (azathioprine, ciclosporin, MMF, oral corticosteroids, or methotrexate) within a 24-month period; or ≥1 of the above immunosuppressive therapies plus ≥1 therapy typically reserved for MG resistant to conventional therapies (i.e. cyclophosphamide, rituximab); or regular treatment with PE, defined as ≥6 claims for treatment on separate dates within a 12-month period. Owing to the inability to distinguish IVIg used as a maintenance treatment from IVIg used as a fast-acting ‘bridge’ therapy, it was not included in the definition for refractory MG | 1,2                           | Retrospective analysis of medical and pharmacy claims data (refractory MG, n = 403; nonrefractory MG, n = 3811) |
| Evoli et al. 2003¹²   | Withdrawal of oral pyridostigmine owing to muscle cramps and excessive salivation; poor tolerance of azathioprine; severe generalized bulbar weakness | 1,3                          | Case series (n = 13)                         |
| Reference          | Definition of refractory MG                                                                                                                                                                                                 | Classification of definition | Comment                        |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|--------------------------------|
| Gladstone et al. 2004<sup>13</sup> | Symptoms of double vision, dysphonia, and dysphagia despite treatment with steroids, plasmapheresis, IVlg, azathioprine, and pyridostigmine                                                                                       | 1                             | Case series (n = 3)            |
| Hewett et al. 2018<sup>14</sup> | Symptomatic despite standard-of-care therapy. Eligible patients had a QMG total score of ≥8, of which ≥4 points were derived from signs other than ocular symptoms.                                                        | 1                             | Phase II study (n = 40)        |
| Howard et al. 2013<sup>15</sup> | Persistent moderate to severe muscle weakness despite treatment with ≥2 immunosuppressive agents, including prednisone for ≥1 year. Eligible patients had a QMG total score of ≥12 and grade ≥2 on ≥4 QMG test items | 1                             | Phase II study (n = 14)        |
| Howard et al. 2017<sup>16</sup> | Eligible patients had an MG-ADL score of ≥6 and MGFA class II–IV disease, and had received treatment with ≥2 immunosuppressive therapies, or ≥1 immunosuppressive therapy with IVlg or PE given ≥4 times per year, for 12 months without symptom control | 1,2                           | Phase III study (n = 125)      |
| Jing et al. 2017<sup>17</sup> | Failure to respond to multiple immunosuppressive therapies, or unacceptable adverse reactions to conventional treatments, or requirement for repeated treatment with IVlg or PE, or frequent myasthenic crises | 1,2,3,5                       | Small study (n = 8)            |
| Kanth et al. 2016<sup>18</sup> | Multiple hospitalizations for MG exacerbations; multiple immunosuppressants; MMF stopped because of refractory symptoms, azathioprine stopped because of elevated liver function tests                                                                                              | 1,3,5                         | Case of PML                   |
| Kovács et al. 2017<sup>19</sup> | Case 1: inadequate response to multiple immunosuppressants including ciclosporin; need for PE or IVlg 2–3 times annually because of marked progression; inability to taper corticosteroids  
Case 2: diagnosed with possible myositis; intolerance to azathioprine, inadequate response to hydroxychloroquine, methylprednisolone, and ciclosporin; PE for deteriorating symptoms | 1,2                           | Case series (n = 2)            |
| Reference                        | Definition of refractory MG                                                                                                                                                                                                 | Classification of definition | Comment                            |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------|
| Landon-Cardinal *et al.* 2018    | Intolerance or inadequate response for >12 months to prednisone and ≥2 other immunosuppressive and/or immunomodulatory agents during the year before inclusion. Inadequate response defined as the absence of improvement or worsening of MG signs and symptoms according to the MGFA postintervention status classification. | 1,3                         | Phase II study (n = 12)           |
| Lebrun *et al.* 2009            | Poor response to at least two successive immunosuppressive therapy schedules (azathioprine 150 mg/day, IV cyclophosphamide 500 mg/month, ciclosporin 100–200 mg/day, or MMF 2 g/day) after thymectomy associated with corticosteroids. | 1                           | Case series (n = 6)               |
| Leuzzi *et al.* 2014            | —                                                                                                                                                                                                                          |                             | No definitions given; study (n = 177) included patients with bulbar symptoms and patients undergoing plasmapheresis or IVIg treatment, suggesting patients with poorly controlled or refractory MG. |
| Meriggioli and Rowin 2000       | Persistent symptoms requiring hospitalization despite prednisolone, azathioprine; subsequent toxicity with azathioprine.                                                                                                                                                       | 1,3                         | Case history                      |
| Pompeo *et al.* 2000            | Inclusion criteria for complete thymectomy: lack of significant symptomatic improvement for ≥3 years after thymectomy; deterioration of symptoms after initial improvement lasting >24 months not adequately controlled by maximal medical therapy or requiring repeated PE cycles; evidence of residual thymic tissue or thymomatous transformation on computed tomography, magnetic resonance imaging, or both. | 1                           | Small study (n = 8)               |
| Ponseti *et al.* 2005           | All patients had MG symptoms despite prednisolone and ciclosporin treatment after thymectomy. Dose of prednisone or ciclosporin could not be reduced. All patients experienced side effects of long-term steroid and ciclosporin.                                       | 1,2,3                       | Small study (n = 13)              |
| Reference                  | Definition of refractory MG                                                                 | Classification of definition $^a$ | Comment                                                                                   |
|----------------------------|--------------------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------------------|
| Ponseti et al. 2005$^{26}$ | Treatment including obesity, hypertrichosis, gingival enlargement, hypertension, hypercholesterolemia, and renal insufficiency | 1,2,3                             | Prospective open-label study ($n = 79$)                                                    |
| Rahul et al. 2017$^{27}$   | Acute aggravation of MG refractory to usual treatment with multiple immunosuppressants, including IVIg, mycophenolate, prednisolone, and five cycles of plasmapheresis | 1                                 | Case history                                                                               |
| Robeson et al. 2017$^{28}$ | Immunosuppression could not be lowered without clinical relapse, inadequate clinical control of the disease during the immunotherapy regimen, or severe adverse events due to current immunosuppressive therapy | 1,2,3                             | Case series ($n = 16$)                                                                     |
| Schneider et al. 2001$^{29}$ | Case 1: only moderate improvement in symptoms under treatment with pyridostigmine, glucocorticoids, azathioprine, and intermittent PE; azathioprine-associated liver toxicity  
Case 2: worsening of bulbar symptoms and weakness of respiratory muscles under treatment with azathioprine; liver toxicity resulting in stopping azathioprine; PE performed  
Case 3: deterioration in muscle weakness under azathioprine and glucocorticoids (post-thymectomy) | 1,3                               | Case series ($n = 3$)                                                                     |
| Sorgun et al. 2014$^{30}$  | Inadequate response to standard therapies, and patients who could not or did not want to receive corticosteroid or immunosuppressive treatment owing to side effects | 1,3                               | Small study ($n = 13$)                                                                    |
| Stieglbauer et al. 2017$^{31}$ | Failure to respond adequately to conventional therapies and/or severe or intolerable side effects | 1,3                               | Retrospective analysis ($n = 4$), 10-year follow-up                                          |
| Sudulagunta et al.         | Immunotherapy for MG could not be reduced without clinical relapse; or MG not clinically controlled on immunotherapy regimen; or developed severe severe | 1,2,3                             | Retrospective analysis ($n = 82$)                                                          |
| Reference                  | Definition of refractory MG                                                                 | Classification of definition\(^a\) | Comment                                      |
|---------------------------|---------------------------------------------------------------------------------------------|------------------------------------|----------------------------------------------|
| 2016\(^{32}\)            | adverse events from immunosuppressive therapy for $\geq 12$ months. Duration of treatment $\geq 1$ year |                                    |                                              |
| Yamada et al. 2015\(^{33}\) | Case 2: need for ongoing PE, serious adverse events related to PE                              | 2,3                                | Case series, MuSK-positive MG               |
|                           | Case 3: need for ongoing PE, serious adverse events related to azathioprine                  |                                    |                                              |
| Zieliński et al. 2004\(^{34}\) | Refractory myasthenic symptoms after a previous transsternal thymectomy, Osserman scale II–V; 67% receiving steroids or other immunosuppressive drugs | 1                                  | Small study ($n = 21$)                      |

\(^a\)Classified according to definitions given in Table 1 in review article.

IV, intravenous; IVIg, intravenous immunoglobulin; MG, myasthenia gravis; MG-ADL, myasthenia gravis activities of daily living; MGFA, Myasthenia Gravis Foundation of America; MMF, mycophenolate mofetil; MuSK, muscle-specific kinase; PE, plasma exchange; PML, progressive multifocal leukoencephalopathy; QMG, quantitative myasthenia gravis.
**Supplementary Table 2.** Acute and long-term side effects of medications used to treat MG.

| Druga and doseb | AEs                                      | Contraindications                                      | Commentsc | Illustrative examples in patients with MG                  |
|-----------------|------------------------------------------|--------------------------------------------------------|-----------|------------------------------------------------------------|
|                 | **Short term**                           | **Long term**                                          |           |                                                            |
| **Acetylcholinesterase inhibitors**       |                                           |                                                       |           |                                                            |
| Pyridostigmine bromide | Muscarinic effects (e.g. nausea, vomiting, diarrhea, abdominal cramps, increased peristaltic and bronchial secretions, increased salivation, miosis, heavy perspiration); nicotinic effects (e.g. muscle cramps, fasciculations, muscle weakness) | Mechanical gastrointestinal or urinary obstruction; Extreme caution required when administering to patients with obstructive respiratory diseases; Pregnancy; lactation | Poorly tolerated or may cause clinical worsening in patients with MuSK antibody-positive MG; AEs occur in at least one-third of patients; US Pregnancy Category C |                                                              |
| Ambenonium chloride | Fewer gastrointestinal side effects than pyridostigmine | Routine administration with atropine; Patients receiving mecamylamine or any other ganglionic-blocking agents | Not available in all countries; Alternative agent for patients with an intolerance to pyridostigmine bromide; US Pregnancy Category C |                                                              |
| **Systemic steroids**               |                                           |                                                       |           |                                                            |
| Glucocorticoids | Neuropsychiatric effects, gastrointestinal irritation, Weight gain, diabetes mellitus, hypertension, Systemic infections; ocular herpes simplex; | Systemic infections; ocular herpes simplex; | US Pregnancy Category C | Chronic steroid use provoked osteoporotic vertebral compression |
| Drug and dose | AEs | Contraindications | Comments | Illustrative examples in patients with MG |
|--------------|-----|-------------------|----------|------------------------------------------|
| Oral therapy: 0.5–1.5 mg/kg IV pulse therapy: 500–1000 mg/day for 1–3 days | skin disorders, susceptibility to infection, initial worsening of MG symptoms | myopathy, osteoporosis, cataracts, cushingoid appearance, steroid myopathy | patients with rare hereditary problems of galactose intolerance; the Lapp lactase deficiency or glucose-galactose malabsorption | fracture, cataract, and chronic central serous chorioretinopathy in a patient with refractory MG |
| Melzer et al. 2016; Moghadam-Kia and Werth 2010; Accord-UK Ltd 2018; Seton Pharmaceuticals 2013 | | | | |
| Steroid-sparing immunosuppressants | | | | |
| Methotrexate (off label) | Gastrointestinal symptoms, interstitial pneumonitis, malaise, fatigue, chills, fever, dizziness, eye irritation, exanthema, leukopenia | Ulcerative stomatitis, myelosuppression, vasculitis, loss of libido/impotence, hepatotoxicity, kidney failure, pulmonary damage, fibrosis, psychiatric disorder, hair loss, osteoporosis, decreased resistance to infection | Active infections, immunodeficiency syndrome(s), renal insufficiency, liver insufficiency, alcohol abuse, pre-existing blood dyscrasias, pregnancy, breast feeding | US Pregnancy Category X |
| 7.5–15 mg once per week; max. 25 mg once per week; in combination with folic acid (5 mg) 24 hours after application | | | | In clinical trials of methotrexate in patients with MG, AEs included nonspecific pain, gastrointestinal complaints, hypertension, and infections |
| Melzer et al. 2016; Hospira UK Ltd 2017; Medac Pharma Inc. 2014 | | | | |
| MMF (off label) | Gastrointestinal symptoms, susceptibility to infection | Bone marrow suppression, risk for lymphoma, edema | Pregnancy, breast feeding | Multiple drug–drug interactions |
| 0.5–3 g/day in two single doses (mostly 2 × 1 g/day) | | | | US Pregnancy Category D |
| Melzer et al. 2016; Teva Pharma BV 2018 | | | | In a phase III clinical trial in patients with MG, MMF was associated with headache, worsening of MG, and nausea; serious AEs occurred in 22% of patients, | |
| Drug<sup>a</sup> and dose<sup>b</sup> | AEs | Contraindications | Comments<sup>c</sup> | Illustrative examples in patients with MG |
| --- | --- | --- | --- | --- |
| Genentech, Inc. 2015<sup>48</sup> | Short term | Long term | | including serious infections<sup>59</sup> |
| Tacrolimus (off label) 0.1–0.2 mg/day/kg in two single doses <sup>35</sup> | Opportunistic infections, nephrotoxicity, CNS toxicity (tremor, headache, posterior reversible encephalopathy syndrome), gastrointestinal conditions, hyperglycemic conditions, photophobia, tinnitus | PML, benign and malignant neoplasms, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, bone marrow suppression, diabetes mellitus, insomnia, skin rashes and erythema, gingival hyperplasia | Multiple drug–drug interactions US Pregnancy Category C | In clinical trials in patients with MG, the most commonly occurring AEs (each occurring in approximately one-third of patients) were an increase in glycated hemoglobin level and an increase in neutrophil count<sup>59</sup> |
| Melzer et al. 2016<sup>35</sup> Katari et al. 1997<sup>55,56</sup> Sandoz Ltd 2017<sup>47</sup> Astellas Pharma US, Inc. 2015<sup>58</sup> | | | Other reported AEs included nasopharyngitis (25% of patients), hypomagnesemia (24%), decreased | |
| Drug<sup>a</sup> and dose<sup>b</sup> | AEs | Contraindications | Comments<sup>c</sup> | Illustrative examples in patients with MG |
|---|---|---|---|---|
| **Short term** | **Long term** | | | |
| Azathioprine (off label in USA) | Viral, fungal, and bacterial infections, gastrointestinal conditions, myelosuppression, phototoxic reactions, hypersensitivity reactions | Pancreatitis, hepatotoxicity, cutaneous hyperkeratosis and skin malignancies | Hypersensitivity to azathioprine or 6-mercaptopurine; severe infections; seriously impaired hepatic or bone marrow function; pancreatitis; any live vaccine, especially BCG, smallpox, and yellow fever; pregnancy unless the benefits outweigh the risks; breast feeding | Multiple drug–drug interactions<br>US Pregnancy Category D<br>AEs reported in case histories of patients with MG include intolerable nausea and abdominal pain, cytomegalovirus and parvovirus infections, and liver toxicity<sup>1,19,23,29,33</sup> |
| Induction dose: 2–3 mg/day/kg | | | | |
| Maintenance dose: 1.5–2 mg/day/kg | | | | |
| Melzer et al. 2016<sup>35</sup>; Accord-UK Ltd 2017<sup>60</sup>; Prometheus Laboratories Inc. 2014<sup>61</sup> | | | | |
| Ciclosporin A (off label) | Opportunistic infection, nephrotoxicity, CNS toxicity (tremor, headache, posterior reversible encephalopathy syndrome), gastrointestinal conditions, hyperglycemic conditions, hyperlipidemia | PML, benign and malignant neoplasms, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, leukopenia, diabetes mellitus, skin rashes and erythema, gingival hyperplasia, hypertrichosis, hirsutism | Combination with products containing Hypericum perforatum; combination with medicines that are substrates for the multidrug efflux transporter P-glycoprotein or the organic anion transporter proteins and for which elevated plasma concentrations | Nephrotoxicity in approximately one-third of patients<br>Multiple drug–drug interactions<br>US Pregnancy Category C<br>In clinical trials of patients with MG who were treated with ciclosporin, the following AEs were reported to result in withdrawal: nephrotoxicity, headache, infection, and gastrointestinal events<sup>64,65</sup> |
| 2 (–5) mg/day/kg in two single doses | | | | |
| Melzer et al. 2016<sup>35</sup>; Generics UK T/A Mylan 2015<sup>62</sup>; Novartis 2015<sup>63</sup> | | | | |
| Drug and dose | AEs | Contraindications | Comments | Illustrative examples in patients with MG |
|---------------|-----|------------------|----------|------------------------------------------|
| Short term    | Long term | are associated with serious and/or life-threatening events; abnormal renal function; uncontrolled hypertension; malignancies; pregnancy; breast feeding | | |
| **Escalation therapy** | | | | In a large case series ($n = 28$) of patients with refractory MG who were treated with rituximab, 39% were reported as having ‘benign’ side effects such as flu-like syndrome, while 14% had severe side effects.

One case of PML was identified in a systematic review of 47 uncontrolled observational studies and case histories comprising a total of 169 patients treated. |
| Rituximab (off label) | | | | |
| 1000 mg IV on days 1 and 15 every 6–9 months | Infusion reaction, infections, Lyell’s syndrome, Stevens–Johnson syndrome, cardiovascular events | PML, hepatitis B reactivation, severe mucocutaneous reactions | Active severe infections, severely immunocompromised state, severe heart failure or severe, uncontrolled cardiac disease, pregnancy (unless the possible benefit outweighs the potential risk), breast feeding | US Pregnancy Category C |
| Drug and dose | AEs | Contraindications | Comments | Illustrative examples in patients with MG |
|--------------|-----|-------------------|----------|------------------------------------------|
|             |     |                   |          | with rituximab<sup>68</sup>| |
|             |     |                   |          | One case of PML was also diagnosed in a patient with refractory MG who had received long-term rituximab<sup>1</sup>| |
| Eculizumab  |     |                   |          | Phase III trial: the most common AEs associated with eculizumab were reported with similar frequency in patients receiving placebo: headache (16% with eculizumab <i>versus</i> 19% with placebo), upper respiratory tract infection (16% <i>versus</i> 19%), nasopharyngitis (15% <i>versus</i> 16%), nausea (13% <i>versus</i> 14%), and diarrhea (13% <i>versus</i> 13%)<sup>16</sup>| |
| Initial phase: 900 mg via a 25- to 45-minute IV infusion every week for the first 4 weeks | Meningococcal infections, other infections, headache, diarrhea | Arthralgia | Unresolved <i>Neisseria meningitidis</i> infection; patients not currently vaccinated against <i>N. meningitidis</i> unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination | Meningococcal infection was uncommon (i.e., incidence of ≥1/1000 to <1/100) in 1407 patients included in 29 eculizumab clinical trials, including patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and refractory generalized MG, as well as from postmarketing experience<sup>70</sup> |
| Maintenance phase: 1200 mg via a 25- to 45-minute IV infusion on week 5, followed by 1200 mg via a 25- to 45-minute IV infusion every 14 ± 2 days |             |                   |          | No meningococcal infections were reported in completed refractory MG clinical studies in which patients received prophylactic antibiotic treatment or |
| Alexion Pharma UK Ltd 2017<sup>36</sup>, Dhillon 2018<sup>69</sup> |             |                   |          | Similar AEs (mainly infections) occurred in 15% of patients receiving eculizumab <i>(versus</i> 29% receiving placebo)<sup>16</sup> | |
|             |             |                   |          | Similar AEs were | |
| Drug\(^a\) and dose\(^b\) | AEs | Contraindications | Comments\(^c\) | Illustrative examples in patients with MG |
|---|---|---|---|---|
| Cyclophosphamide (off label) | Gastrointestinal symptoms, infection, fever, chills, asthenia, malaise, alopecia, cystitis | Liver dysfunction, bone marrow suppression, malignancies | Acute infections, bone marrow aplasia or bone marrow depression, urinary tract infection, urinary outflow obstruction, pregnancy, breast feeding | US Pregnancy Category D |
| Pulse therapy: 500–750 mg/m\(^2\) IV every 4–8 weeks under urothelial protection with mesna |  |  |  | High-dose cyclophosphamide treatment resulted in neutropenic fever in 7/12 patients (58%) with refractory MG, resulting in readmission to hospital for antibiotic treatment\(^75\) In four of these patients, neutropenic fever was attributable to diverticulitis, axilla abscess, line infection, and mycoplasma |
| Melzer et al. 2016;\(^{36}\) Sandoz Ltd 2017;\(^{73}\) Baxter International Inc. 2013\(^74\) |  |  |  |  |

According to the Centers for Disease Control and Prevention, 16 cases of meningococcal disease (including one fatality) were identified in patients in the USA who received eculizumab (mainly for paroxysmal nocturnal hemoglobinuria) between 2008 and 2016\(^71\) reported in the extension study: headache (27%), nasopharyngitis (24%), and diarrhea (14%)\(^72\)

Cyclophosphamide (off label) |  |  |  |  |
| Drug<sup>a</sup> and dose<sup>b</sup> | AEs | Contraindications | Comments<sup>c</sup> | Illustrative examples in patients with MG |
|---|---|---|---|---|
| | | | | pneumonitis; the cause was unknown in the other three patients<sup>75</sup> |
| **Intervention therapies** | | | | |
| IVlg (off label) | | | | |
| 0.4 g/kg/day on 5 consecutive days, or 1 g/kg/day on 2 consecutive days | Headache, fever or chills, nausea, hypertension, allergic/anaphylactic reactions, dermatitis, pulmonary edema, venous thrombosis, aseptic meningitis, hemolysis, serum creatinine concentration elevations | Infection (HIV or viral hepatitis) | Renal failure, hypercoagulable states, hypersensitivity to immunoglobulin | AEs associated with IVlg in clinical trials in patients with MG include moderate fever, nausea, and headache<sup>77</sup> Delayed AEs may include thrombotic events (including stroke), neurological disorders, renal impairment, hematologic disorders, electrolyte disturbance, aseptic meningitis, and transfusion-related infection<sup>79</sup> |
| Melzer et al. 2016;<sup>35</sup> Sanders et al. 2016;<sup>76</sup> Gajdos et al. 2012;<sup>77</sup> Barth et al. 2011<sup>78</sup> | | | | |
| Plasmapheresis | Arterial bleeding, bleeding disorders, infections, septicemia, venous thrombosis, nausea, hypotension, citrate | Sepsis | Sepsis | Individual cases of catheter-related infection and sepsis, alterations in hemostasis and |
| Gajdos et al. 2012;<sup>77</sup> Barth et al. 2011;<sup>78</sup> Heatwole et al. 2011;<sup>80</sup> Köhler et al. 2011<sup>81</sup> | | | | |
| Drug\(^a\) and dose\(^b\) | AEs | Contraindications | Comments\(^c\) | Illustrative examples in patients with MG |
|--------------------------|-----|------------------|-----------------|---------------------------------|
|                          |     | Short term | Long term |                                   |                                 |
|                          |     | reaction, vasospasm, vasovagal reaction |                  | hydrothorax in patients with refractory MG treated with PE\(^{19,33}\) |
|                          |     |           |           | AEs in clinical studies in patients with MG treated with PE include hypotension, hemolysis, hematoma, septicemia, fever, and thrombosis\(^{61,82}\) |
| Immunoabsorption Köhler et al. 2011\(^{81}\) | Tachycardia, bradycardia, hypotension, dyspnea, hemorrhage | Sepsis (depending on clinical condition) | | |

\(^a\)Designated ‘off label’ if not indicated for use in MG in Europe and/or the USA.

\(^b\)Melzer et al 2016;\(^{35}\) except eculizumab: Alexion Pharma UK Ltd 2017.\(^{36}\)

\(^c\)Pregnancy categories no longer assigned in the USA after 30 June 2015.

AE, adverse event; BCG, bacillus Calmette-Guérin; CNS, central nervous system; HIV, human immunodeficiency virus; IV, intravenous; IVIg, intravenous immunoglobulin; MG, myasthenia gravis; MMF, mycophenolate mofetil; MuSK, muscle-specific kinase; PE, plasma exchange; PML, progressive multifocal leukoencephalopathy; USA, United States of America.
References

1. Afanasiev V, Demeret S, Bolgert F, et al. Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients. *Neuromuscul Disord* 2017; 27: 251–258.

2. Ando T, Omasa M, Kondo T, et al. Predictive factors of myasthenic crisis after extended thymectomy for patients with myasthenia gravis. *Eur J Cardiothorac Surg* 2015; 48: 705–709.

3. Baek WS, Bashey A and Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. *J Neurol Neurosurg Psychiatry* 2007; 78: 771.

4. Barnett C, Wilson G, Barth D, et al. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. *J Neurol Neurosurg Psychiatry* 2013; 84: 94–97.

5. Beecher G, Anderson D and Siddiqi ZA. Rituximab in refractory myasthenia gravis: extended prospective study results. *Muscle Nerve* 2018; 58: 452–455.

6. Blaha M, Pit'tha J, Blaha V, et al. Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis. *J Biomed Biotechnol* 2010; 2010: 419520.

7. Bourque PR, Pringle CE, Cameron W, et al. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study. *PLoS One* 2016; 11: e0159993.

8. Buzzard KA, Meyer NJ, Hardy TA, et al. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. *Muscle Nerve* 2015; 52: 204–210.

9. Cereda E, Beltramolli D, Pedrolli C, et al. Refractory myasthenia gravis, dysphagia and malnutrition: a case report to suggest disease-specific nutritional issues. *Nutrition* 2009; 25: 1067–1072.

10. Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. *Muscle Nerve* 2012; 46: 687–691.

11. Engel-Nitz NM, Boscoe A, Wolbeck R, et al. Burden of illness in patients with treatment refractory myasthenia gravis. *Muscle Nerve* 2018; 58: 99–105.

12. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. *Brain* 2003; 126: 2304–2311.

13. Gladstone DE, Brannagan TH III, Schwartzman RJ, et al. High dose cyclophosphamide for severe refractory myasthenia gravis. *J Neurol Neurosurg Psychiatry* 2004; 75: 789–791.
14. Hewett K, Sanders DB, Grove RA, et al; BEL115123 Study Group. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 2018; 90: e1425–e1434.

15. Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48: 76–84.

16. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16: 976–986.

17. Jing S, Song Y, Song J, et al. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. J Neuroimmunol 2017; 311: 14–21.

18. Kanth KM, Solorzano GE and Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 2016; 6: e17–e19.

19. Kovács E, Dankó K, Nagy-Vince M, et al. Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin. Ther Adv Neurol Disord 2017; 10: 363–366.

20. Landon-Cardinal O, Friedman D, Guiguet M, et al. Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis. J Neuromuscul Dis 2018; 5: 241–249.

21. Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009; 16: 246–250.

22. Leuzzi G, Meacci E, Cusumano G, et al. Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. Eur J Cardiothorac Surg 2014; 45: e76–e78.

23. Meriggioli MN and Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000; 23: 1287–1289.

24. Pompeo E, Nofroni I, lavicoli N, et al. Thoracoscopic completion thymectomy in refractory nonthymomatous myasthenia. Ann Thorac Surg 2000; 70: 918–923.

25. Ponseti JM, Azem J, Fort JM, et al. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005; 107: 187–190.

26. Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporin- and prednisolone-dependent myasthenia gravis. Neurology 2005; 64: 1641–1643.
27. Rahul LY, Dakua T and Mukherjee A. Refractory myasthenia gravis treated successfully with rituximab: a case report. Ann Indian Acad Neurol 2017; 20: 436–437.

28. Robeson KR, Kumar A, Keung B, et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 2017; 74: 60–66.

29. Schneider C, Gold R, Reiners K, et al. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001; 46: 79–82.

30. Sorgun MH, Sener HO, Yucesan C, et al. Intravenous immunoglobulin for prophylaxis of acute exacerbation in myasthenia gravis. Neurol Sci 2014; 35: 891–896.

31. Stieglbauer K, Pichler R and Topakian R. 10-year-outcomes after rituximab for myasthenia gravis: efficacy, safety, costs of inhospital care, and impact on childbearing potential. J Neurol Sci 2017; 375: 241–244.

32. Sudulagunta SR, Sepehrar M, Sodalagunta MB, et al. Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab. Ger Med Sci 2016; 14: Doc12.

33. Yamada C, Teener JW, Davenport RD, et al. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients. J Clin Apher 2015; 30: 314–319.

34. Zieliński M, Kuzdzał J, Staniec B, et al. Extended rethymectomy in the treatment of refractory myasthenia gravis: original video-assisted technique of resternotomy and results of the treatment in 21 patients. Interact Cardiovasc Thorac Surg 2004; 3: 376–380.

35. Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 2016; 263: 1473–1494.

36. Alexion Pharma UK Ltd. Soliris (summary of product characteristics). Stockley Park, UK: Alexion Pharma UK Ltd, 2017.

37. Maggi L and Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig 2011; 31: 691–701.

38. Mylan Products Ltd. Mestinon 60 mg tablets (summary of product characteristics). Potters Bar, UK: Mylan Products Ltd, 2018.

39. Drugs.com. Antimyasthenics (systemic) monograph. https://www.drugs.com/mmx/ambenonium-chloride.html#citec00106710 (1994, accessed 17 September 2018).
40. Moghadam-Kia S and Werth VP. Prevention and treatment of systemic glucocorticoid side effects. *Int J Dermatol* 2010; 49: 239–248.

41. Accord-UK Ltd. Prednisolone 30 mg tablets (summary of product characteristics). Barnstaple, UK: Accord UK Ltd, 2018.

42. Seton Pharmaceuticals. Prednisolone sodium phosphate oral solution (prescribing information). Manasquan, USA: Seton Pharmaceuticals, 2013.

43. Hospira UK Ltd. Methotrexate 10 mg tablets (summary of product characteristics). Maidenhead, UK: Hospira UK Ltd, 2017.

44. Medac Pharma Inc. RASUVO™ (methotrexate) injection, for subcutaneous use (highlights of prescribing information). Chicago, USA: Medac Pharma Inc., 2014.

45. Pasnoor M, He J, Herbelin L, *et al*. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. *Neurology* 2016; 87: 57–64.

46. Heckmann JM, Rawoot A, Bateman K, *et al*. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. *BMC Neurol* 2011; 11: 97.

47. Teva Pharma BV. Mycophenolate mofetil (Myfenax) 500 mg tablets (summary of product characteristics). Harlow, UK: Teva Pharma BV, 2018.

48. Genentech, Inc. CellCept (medication guide). South San Francisco, USA: Genentech, Inc., 2015.

49. Sanders DB, Hart IK, Mantegazza R, *et al*. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. *Neurology* 2008; 71: 400–406.

50. Meriggioli MN, Ciafaloni E, Al-Hayk KA, *et al*. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. *Neurology* 2003; 61: 1438–1440.

51. Levin N, Mali A and Karussis D. Severe skin reaction related to mycophenolate mofetil for myasthenia gravis. *Clin Neuropharmacol* 2005; 28: 152–153.

52. Vernino S, Salomao DR, Habermann TM, *et al*. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. *Neurology* 2005; 65: 639–641.

53. Draper HM. Depressive disorder associated with mycophenolate mofetil. *Pharmacotherapy* 2008; 28: 136–139.

54. Bernardo DR Jr and Chahin N. Toxoplasmic encephalitis during mycophenolate mofetil immunotherapy of neuromuscular disease. *Neuro Immunol Neuroinflamm* 2015; 2: e63.
55. Katari SR, Magnone M, Shapiro R, et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. *Clin Transplant* 1997; 11: 237–242.

56. Katari SR, Magnone M, Shapiro R, et al. Tacrolimus nephrotoxicity after renal transplantation. *Transplant Proc* 1997; 29: 311.

57. Sandoz Ltd. Adoport 5 mg capsules, hard (summary of product characteristics). Camberley, UK: Sandoz Ltd, 2017.

58. Astellas Pharma US, Inc. PROGRAF® (tacrolimus) capsules, USP PROGRAF® (tacrolimus) injection, for intravenous use (highlights of prescribing information). Northbrook, USA: Astellas Pharma US, Inc., 2015.

59. Zhang Z, Yang C, Zhang L, et al. Efficacy and safety of tacrolimus in myasthenia gravis: a systematic review and meta-analysis. *Ann Indian Acad Neurol* 2017; 20: 341–347.

60. Accord-UK Ltd. Azathioprine 50 mg tablets (summary of product characteristics). Barnstaple, UK: Accord UK Ltd, 2017.

61. Prometheus Laboratories Inc. IMURAN (azathioprine) 50-mg scored tablets (product information). San Diego, USA: Prometheus Laboratories Inc., 2014.

62. Generics UK T/A Mylan. Capimune 100 mg, soft capsules (summary of product characteristics). Hatfield, UK: Generics UK T/A Mylan, 2015.

63. Novartis. NEORAL® soft gelatin capsules (cyclosporine capsules, USP), NEORAL® oral solution (cyclosporine oral solution, USP) (prescribing information). East Hanover, USA: Novartis, 2015.

64. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. *N Engl J Med* 1987; 316: 719–724.

65. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. *Ann N Y Acad Sci* 1993; 681: 539–551.

66. Roche Products Ltd. MabThera 500 mg concentrate for solution for infusion (summary of product characteristics). Welwyn Garden City, UK: Roche Products Ltd, 2018.

67. Genentech, Inc. RITUXAN® (rituximab) injection, for intravenous use (highlights of prescribing information). South San Francisco, USA: Genentech, Inc., 2018.

68. Tandan R, Hehir MK II, Waheed W, et al. Rituximab treatment of myasthenia gravis: a systematic review. *Muscle Nerve* 2017; 56: 185–196.

69. Dhillon S. Eculizumab: a review in generalized myasthenia gravis. *Drugs* 2018; 78: 367–376.
70. Alexion Pharmaceuticals Inc. SOLIRIS® (eculizumab) injection, for intravenous use (highlights of prescribing information). New Haven, USA: Alexion Pharmaceuticals Inc., 2017.

71. McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep 2017; 66: 734–737.

72. Howard J, Wang JJ, O’Brien F, et al. Efficacy of eculizumab on myasthenia gravis-activities of daily living and its respiratory, bulbar, limb, and ocular domains in patients with AChR+ refractory generalized myasthenia gravis. The American Association of Neuromuscular & Electromyologistic Medicine Annual Meeting, Phoenix, Arizona, USA, 13–16 September 2017, Abstract #210.

73. Sandoz Ltd. Cyclophosphamide 500 mg powder for solution for injection or infusion (summary of product characteristics). Camberley, UK: Sandoz Ltd, 2017.

74. Baxter International Inc. Cyclophosphamide injection, for intravenous use; cyclophosphamide tablets, for oral use (highlights of prescribing information). Deerfield, USA: Baxter International Inc., 2013.

75. Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 305–314.

76. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87: 419–425.

77. Gajdos P, Chevret S and Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012; 12: CD002277.

78. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVlg and PLEX in patients with myasthenia gravis. Neurology 2011; 76: 2017–2023.

79. Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin. Therapy Front Immunol 2018; 9: 1299.

80. Heatwole C, Johnson N, Holloway R, et al. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 2011; 13: 85–94.

81. Köhler W, Bucka C and Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 2011; 26: 347–355.

82. Gajdos P, Chevret S and Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; 4: CD002275.